RBC upgrades Medical Facilities to “outperform”

RBC Capital Markets has upgraded its rating of Medical Facilities (TSX: DR.UN) to “outperform” and increased its 12-month price target to $10.00 from $9.50.   The units finished trading at $8.44 yesterday. Medical Facilities owns controlling interests in four specialty surgical hospitals, located in South Dakota and Oklahoma, as well as two ambulatory surgery centers [...]

New data from YM’s nimotuzumab

YM BioSciences (TSX:YM; AMEX:YMI) of Mississauga and its European partner Oncoscience have reported additional data from a Phase 3 study of YM’s nimotuzumab drug in children with an inoperable form of brain cancer. “These results demonstrate that nimotuzumab continues its long record of differentiated and remarkable safety and that it brings important benefits to children [...]

Amorfix perfect testing vCJD France

Amorfix Life Sciences (TSX:AMF) has achieved 100% specificity, or no reproducible false positive results, after testing 19,000 blood donations for variant Creutzfeldt-Jakob Disease, the human version of mad cow disease, with its EP-vCJD blood-screening assay in France. “Our France study has demonstrated the feasibility of implementing the Amorfix test and has provided confidence that very [...]

Waiting on Medicago trial results

In a New Idea of Interest report on Medicago (TSX-V:MDG), Dundee Securities said that if Phase 1 results for its lead H5N1 avian vaccine are positive in December, the company could “establish a leading position in the global effort to find a superior vaccine-production technology.” Analyst David Martin rates the stock “buy (speculative risk)” but [...]

Critical Outcome MOA on COTI-2

Critical Outcome Technologies (TSX-V:COT) for the first time has outlined the specific cellular target and mechanism of action for its lead oncology candidate COTI-2. “We have now demonstrated through a series of key experiments that the Pleckstrin Homology domain of (the protein) AKT/AKT2 is a selective cellular target for COTI-2,” Critical Outcome president Dr. Wayne [...]

Microbix hits 52-week high on flu vaccine plant

Shares of Microbix Biosystems (TSX:MBX) touched a 52-week high of 66 cents in early Tuesday trading after the company unveiled a joint venture to provide initial financing to build Asia’s largest flu vaccine production plant in China’s Hunan province. The $200-million plant will have an annual capacity to produce more than 100 million doses of [...]

Amorfix detects vCJD prions in non-human primates

Amorfix Life Sciences (TSX:AMF) has taken a giant step in readying a screening test for the human version of mad cow disease by reporting that it detected abnormal proteins or prions responsible for the disease in monkey blood. “It’s fantastic for our test,” George Adams, CEO of Amorfix, told Andy Georgiades of Dow Jones newservice, [...]

Cannasat lighting up THC drug

Twenty-year cancer survivor Sara Lee Irwin is a passionate advocate for the pain relieving benefits of medicinal cannabis drugs and health risks of chronic use of opioid medicines. “Nothing beats opioids for blunt-hammer pain and trauma, but for chronic, life-long pain management, cannabinoids are the better choice,” she says in an exclusive interview with biotuesdays.com. [...]

Theratechnologies posts new tesamorelin data

Montreal-based Theratechnologies (TSX:TH) presented additional data about its lead tesamorelin drug to treat excess abdominal fat in HIV patients with lipodystrophy at an HIV conference in Philadelphia. In a statement, the company said results indicated that after 26 weeks of treatment the 543 patients treated with 2 mille-grams daily of tesamorelin reported “clinically relevant improvements [...]

Stellar gets South Korea distributor for Uracyst

Stellar Pharmaceuticals (OTCBB:SLXCF) has signed a licensing agreement for the distribution and sale of one of its lead products, Uracyst, to treat interstitial cystitis/painful bladder syndrome in South Korea with Jeilmedix Pharmaceutical. Peter Riehl, Stellar’s CEO, said in a statement that the accord is in line with the company’s strategy of selling direct in Canada [...]

Next Page »